Physician profile
Sheilagh Maguiness
NPI 1679796429
$21,566.54
in general payments reported to CMS, 2019-2025
8 companies · $6,455 in 2025
The $6,455 reported for 2025 was more than what 85% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.21 · 2023: $8,250 · 2024: $6,848 · 2025: $6,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,558 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,713 · Honoraria: $1,500 · Travel and Lodging: $1,178 · Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,558.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,712.50 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,177.92 |
| Food and Beverage | $603.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17,024.47 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $2,850.61 | 2024-2025 | Zoryve |
| Lnhc, INC | $1,500.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $80.42 | 2024-2025 | Dupixent |
| Pierre Fabre Pharmaceuticals, INC. | $49.78 | 2024 | Hemangeol |
| Nobelpharma America, LLC | $47.05 | 2025 | |
| Kci USA, INC. | $14.21 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheilagh Maguiness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.